oa TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF?

References

1. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, V McMurray JJ, Michelson EL, Olofsson B, Ostergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. Sep. 2003; 362:9386:777–781.
   [Google Scholar]
2. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. Oct. 2006; 27:19:2338–2345.
   [Google Scholar]
3. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. Dec. 2008; 359:23:2456–2467.
   [Google Scholar]
4. Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. Feb. 2005; 26:3:215–225.
   [Google Scholar]
5. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, Love TE, Aronow WS, Adams KF, Gheorghiade M. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. Aug. 2006; 114:5:397–403.
   [Google Scholar]
6. Desai AS, Lewis EF, Li R, Solomon SD, Assmann SF, Boineau R, Clausell N, Diaz R, Fleg JL, Gordeev I, McKinlay S, O'Meara E, Shaburishvili T, Pitt B, Pfeffer MA. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J. Dec. 2011; 162:6:966. e10–972. e10.
   [Google Scholar]
7. Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res. Mar. 2004; 61:4:663–670.
   [Google Scholar]
8. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. Sep. 1999; 341:10:709–717.
   [Google Scholar]
9. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther. Jan. 2001; 15:1:79–87.
   [Google Scholar]
10. Zannad F, V McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. Jan. 2011; 364:1:11–21.
    [Google Scholar]
11. Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation. Aug. 2004; 110:5:558–565.
    [Google Scholar]
12. Daniel KR, Wells G, Stewart K, Moore B, Kitzman DW. Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure. Congest Heart Fail. 15:2:68–74.
    [Google Scholar]
13. Pieske BM. ALDO-DHF: aldosterone receptor blockade in diastolic heart failure. European Society of Cardiology 2012 Congress, Munich, Germany. [Online]. Available: http://www.eurekalert.org/pub_releases/2012-08/esoc-tas082612.php. [Accessed 05 Sep 2012].
    [Google Scholar]
14. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis. Mar. 2005; 47:5:320–332.
    [Google Scholar]
15. Bhatia RS, V Tu J, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. Jul. 2006; 355:3:260–269.
    [Google Scholar]
16. Shah AM, Shah SJ, Anand IS, Sweitzer NK, O'Meara E, Heitner JF, Sopko G, Li G, Assmann SF, McKinlay SM, Pitt B, Pfeffer MA, Solomon SD. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail. Nov. 2013;, doi: 10.1161/CIRCHEARTFAILURE.113.000887.
    [Google Scholar]
17. Paulus WJ, van Ballegoij JJM. Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol. Feb. 2010; 55:6:526–537.
    [Google Scholar]
18. ElGuindy A, Yacoub M. Heart failure with preserved ejection fraction. GCSP. 2012:10, http://dx.doi.org/10.5339/gcsp.2012.10 .
    [Google Scholar]